<DOC>
	<DOCNO>NCT00028899</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop cancer cell divide stop grow die . Monoclonal antibody gemtuzumab ozogamicin locate cancer cell either kill deliver cancer-killing substance without harm normal cell . Combining monoclonal antibody therapy combination chemotherapy may kill cancer cell . PURPOSE : Phase I trial study effectiveness combine gemtuzumab ozogamicin combination chemotherapy treat child relapse refractory acute myeloid leukemia myelodysplastic syndrome .</brief_summary>
	<brief_title>Monoclonal Antibody Plus Chemotherapy Treating Young Patients With Relapsed Refractory Acute Myeloid Leukemia Myelodysplastic Syndromes</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety maximum tolerate dose gemtuzumab ozogamicin combination conventional chemotherapy patient relapse refractory acute myeloid leukemia myelodysplastic syndrome . - Determine efficacy regimen patient . - Correlate likelihood leukemic blast cell undergo apoptosis vitro efficacy regimen patient . - Correlate drug resistance manifest dye efflux multiple drug resistance-1 expression leukemic blast cell efficacy regimen patient . OUTLINE : This dose-escalation , multicenter study gemtuzumab ozogamicin . Patients assign cohort 1 2 treatment regimen . - Regimen A : Patients receive cytarabine IV 2 hour every 12 hour day 1-4 , mitoxantrone IV 1 hour day 3-6 , gemtuzumab ozogamicin IV 2 hour day 7 . - Regimen B : Patients receive cytarabine IV 3 hour every 12 hour day 1 , 2 , 8 , 9 , asparaginase intramuscularly day 2 9 , gemtuzumab ozogamicin IV 2 hour day 3 . Cohorts 3-6 patient receive de-escalating dos gemtuzumab ozogamicin maximum tolerate dose ( MTD ) determine . The MTD define dose 2 3 2 6 patient experience dose-limiting toxicity . Patients follow monthly 6 month , every 2 month 6 month , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A total 52 patient accrue study within 1.5 year .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Gemtuzumab</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis primary acute myeloid leukemia ( AML ) myelodysplastic syndrome Relapsed ( remission duration less 1 year ) OR Failed induction ( failed achieve initial complete response ) Patients AML second malignant neoplasm allow provide prior therapy AML M2 M3 bone marrow aspirate time study entry No Fanconi 's anemia No known CNS leukemia PATIENT CHARACTERISTICS : Age : 21 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin great 1.5 time normal AST ALT less 2.5 time upper limit normal No history venoocclusive disease liver define weight increase 5 % baseline serum bilirubin great 5 mg/dL within 20 day receipt chemotherapy Renal : Creatinine great 1.5 time normal OR Creatinine clearance radioisotope glomerular filtration rate ( GFR ) least 70 mL/min OR Equivalent GFR institutional normal range Cardiovascular : Shortening fraction 27 % echocardiogram normal institution OR Ejection fraction 50 % MUGA Other : Not pregnant nursing PRIOR CONCURRENT THERAPY : Biologic therapy : At least 180 day since prior hematopoietic stem cell transplantation Chemotherapy : Not specify Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
</DOC>